Success Metrics

Active Trials

7(88%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

8(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(7)

Terminated(1)

Detailed Status

Recruiting4

Active, not recruiting3

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1

Trials by Phase

Phase 18 (100.0%)

Trials by Status

withdrawn113%

recruiting450%

active_not_recruiting338%

Recent Activity

7 active trials

Showing 5 of 8

active_not_recruitingphase_1

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

NCT04388852

recruitingphase_1

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

NCT06807632

recruitingphase_1

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

NCT05683171

active_not_recruitingphase_1

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

NCT03930953

recruitingphase_1

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07244341

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT04388852Phase 1

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Active Not Recruiting

NCT06807632Phase 1

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

Recruiting

NCT05683171Phase 1

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Recruiting

NCT03930953Phase 1

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Active Not Recruiting

NCT07244341Phase 1

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Recruiting

NCT05633979Phase 1

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

Active Not Recruiting

NCT06294548Phase 1

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Recruiting

NCT05879484Phase 1

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8